STRIANT Drug Patent Profile

Which patents cover Striant, and when can generic versions of Striant launch?

Striant is a drug marketed by Auxilium Pharms Llc and is included in one NDA.

The generic ingredient in STRIANT is testosterone. There are sixty-nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Striant

A generic version of STRIANT was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for STRIANT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for STRIANT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Auxilium Pharms Llc	STRIANT	testosterone	TABLET, EXTENDED RELEASE;BUCCAL	021543-001	Jun 19, 2003		DISCN	Yes	No

International Patents for STRIANT

See the table below for patents covering STRIANT around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3485995
China	1323201
Georgia, Republic of	P20033077	Extended Release Hydrated Bioadhesive Tablet
Morocco	24964
Canada	2341375	COMPRIME BIOADHESIF A LIBERATION PROLONGEE DESTINE A ETRE ADMINISTRE PAR VOIE ORALE (EXTENDED RELEASE BUCCAL BIOADHESIVE TABLET)
Argentina	016650	UNA COMPOSICION FARMACEUTICA PARA ADMISTRACIoN VAGINAL Y SU USO

Investment Scenario and Fundamentals Analysis of STRIANT

Last updated: March 4, 2026

What is STRIANT?

STRIANT is a transdermal testosterone gel indicated for testosterone replacement therapy (TRT) in adult males with hypogonadism. Manufactured by Medicure Inc., it received FDA approval in 2014. The drug aims to address testosterone deficiency by delivering hormone directly through the skin.

Market Overview

The global testosterone replacement therapy market was valued at approximately USD 2.05 billion in 2021 and is projected to reach USD 4.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of nearly 8%[1].

Key Drivers:

• Aging male population.
• Increasing prevalence of hypogonadism.
• Growing acceptance of TRT in clinical practice.

Competitor Landscape:

STRIANT competes with brands such as AndroGel, Testim, Axiron, and compounded testosterone formulations. Market share dynamics favor well-established brands with broader physician familiarity and insurance coverage.

Fundamentals of STRIANT

Regulatory Status

• FDA approval in 2014.
• Approved as a prescription drug for adult males with hypogonadism.
• No major recent regulatory updates.

Commercial Performance

• Limited sales data publicly available; Medicure’s 2022 annual report indicates minimal revenue contributions from STRIANT.
• Lack of significant marketing and distribution channels compared to dominant TRT brands.

Manufacturing and Supply

• Manufactured using standard transdermal gel formulation techniques.
• Reliant on raw material supply chains, with potential vulnerability to raw material shortages.

Patent and Patent Expiry

• The original patent expired in 2019[2].
• Generic competition is expected to increase, pressuring pricing and margins.

Pricing and Reimbursement

• Prescribed primarily in specialized clinics.
• Average wholesale price (AWP) estimated at USD 200-250 per month per patient.
• Reimbursement varies by insurer; coverage limited compared to more established competitors.

Investment Considerations

Aspect	Evaluation	Implication
Market Position	Niche player with limited brand recognition	Difficult to gain significant market share without substantial investment or innovation
Patent Landscape	Patent expired; facing generic competition	Pressure on prices and margins; increased market penetration challenge
Clinical Adoption	Limited awareness among physicians	Additional marketing needed; slow adoption trajectory
Regulatory Environment	Stable with no recent changes	No immediate regulatory hurdles for approval or renewal
Revenue Potential	Modest, given current market penetration and competition	High growth potential if positioned correctly, but risks exist due to competition and reimbursement hurdles

Strategic Outlook

• Short-Term: Limited revenue growth; focus on building awareness and expanding distribution channels.
• Medium to Long-Term: Potential for market share gains through formulation improvements, pricing strategies, or clinical campaign investments.
• Risks: Increased generics, market saturation, and reimbursement limitations threaten profitability.

Key Metrics & Valuation Indicators

• Market size and growth rate forecast.
• Patent expiration timeline.
• Competitive intensity and brand loyalty.
• Pricing trends in TRT segment.
• Regulatory landscape stability.

Conclusion

STRIANT functions within a highly competitive and evolving TRT market. Its current market position is weak, with patent expiry and limited brand recognition adding pressure. Investment in STRIANT requires a clear strategy to address these fundamentals, focusing on differentiation or niche targeting.

---

Key Takeaways

• STRIANT is a testosterone replacement therapy gel with limited current market traction.
• The product faces intense competition from well-established brands.
• Patent expiry in 2019 has increased vulnerability to generics.
• Market growth is promising but challenging due to reimbursement and brand loyalty issues.
• Strategic investments should aim at increasing market penetration, formulation differentiation, or clinical endorsement.

---

FAQs

1. Is STRIANT likely to gain market share given patent expiration?
   Limited without significant marketing or formulation innovation; facing competition from generics.

2. What are the main barriers for STRIANT’s expansion?
   Brand recognition, reimbursement limitations, and established competitors dominate the TRT market.

3. Can regulatory changes impact STRIANT?
   No recent regulatory updates; future changes could influence approval or coverage, but none are imminent.

4. How does pricing affect STRIANT’s competitiveness?
   Pricing at USD 200-250 per month is comparable but still higher than some generics, which could pressure profitability.

5. What opportunities exist for investors?
   Niche market positioning, differentiation through product reformulation, or clinical evidence campaigns could provide growth opportunities.

---

References

[1] Markets and Markets. (2022). Testosterone Replacement Therapy Market.
[2] U.S. Patent and Trademark Office. (2019). Patent expiry summaries for testosterone formulations.